Elaine M Quinet

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi request reprint Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor
    Elaine M Quinet
    Departments of Cardiovascular Metabolic Diseases, Wyeth Research, Collegeville, PA 19246, USA
    J Lipid Res 45:1929-42. 2004
  2. ncbi request reprint Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting
    Elaine M Quinet
    Department of Cardiovascular Metabolic Diseases, Wyeth Research, 500 Arcola Road, RN2229, Collegeville, PA 19426, USA
    Mol Pharmacol 70:1340-9. 2006
  3. doi request reprint Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist
    Baihua Hu
    Chemical Sciences, Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, USA
    J Med Chem 53:3296-304. 2010
  4. pmc LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse
    Elaine M Quinet
    Department of Cardiovascular Metabolic Diseases and Nuclear Receptor Biology, Wyeth Research, Collegeville, PA, USA
    J Lipid Res 50:2358-70. 2009
  5. pmc Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells
    Elizabeth A DiBlasio-Smith
    Department of Biological Technologies, Wyeth Research, 35 CambridgePark Drive, Cambridge, MA 02140, USA
    J Transl Med 6:59. 2008
  6. doi request reprint Identification of 5α, 6α-epoxycholesterol as a novel modulator of liver X receptor activity
    Thomas J Berrodin
    Women s Health and Musculoskeletal Biology, Wyeth Research, Collegeville, PA, USA
    Mol Pharmacol 78:1046-58. 2010
  7. ncbi request reprint Design, synthesis, and biological evaluation of thio-containing compounds with serum HDL-cholesterol-elevating properties
    Hassan Elokdah
    Medicinal Chemistry, Wyeth Research, CN 8000, Princeton, New Jersey 08543, USA
    J Med Chem 47:681-95. 2004
  8. ncbi request reprint Modulation of adipose tissue development by pharmacological inhibition of PAI-1
    David L Crandall
    Cardiovascular and Metabolic Disease Research, Wyeth Research, N2265A, PO Box 42528, Philadelphia, PA 19101, USA
    Arterioscler Thromb Vasc Biol 26:2209-15. 2006

Detail Information

Publications8

  1. ncbi request reprint Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor
    Elaine M Quinet
    Departments of Cardiovascular Metabolic Diseases, Wyeth Research, Collegeville, PA 19246, USA
    J Lipid Res 45:1929-42. 2004
    ..DMHCA and related gene-selective ligands of LXR may have application to the study and treatment of atherosclerosis...
  2. ncbi request reprint Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting
    Elaine M Quinet
    Department of Cardiovascular Metabolic Diseases, Wyeth Research, 500 Arcola Road, RN2229, Collegeville, PA 19426, USA
    Mol Pharmacol 70:1340-9. 2006
    ..In summary, selective LXRbeta activation is expected to stimulate ABCA1 gene expression in macrophages, contribute to favorable HDL increases, but circumvent hepatic LXRalpha-dominated lipogenesis...
  3. doi request reprint Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist
    Baihua Hu
    Chemical Sciences, Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, USA
    J Med Chem 53:3296-304. 2010
    ..These results suggest quinoxaline 13 may have an improved biological profile for potential use as a therapeutic agent...
  4. pmc LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse
    Elaine M Quinet
    Department of Cardiovascular Metabolic Diseases and Nuclear Receptor Biology, Wyeth Research, Collegeville, PA, USA
    J Lipid Res 50:2358-70. 2009
    ..WAY-252623 displays a unique and favorable pharmacological profile suggesting synthetic LXR ligands with these characteristics may be suitable for evaluation in patients with atherosclerotic dyslipidemia...
  5. pmc Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells
    Elizabeth A DiBlasio-Smith
    Department of Biological Technologies, Wyeth Research, 35 CambridgePark Drive, Cambridge, MA 02140, USA
    J Transl Med 6:59. 2008
    ..Anti-atherosclerotic effects of synthetic LXR agonists in murine models suggest clinical utility for such compounds...
  6. doi request reprint Identification of 5α, 6α-epoxycholesterol as a novel modulator of liver X receptor activity
    Thomas J Berrodin
    Women s Health and Musculoskeletal Biology, Wyeth Research, Collegeville, PA, USA
    Mol Pharmacol 78:1046-58. 2010
    ..These results clearly demonstrate that 5,6-EC is an LXR modulator that may play a role in the development of lipid disorders, such as atherosclerosis, by antagonizing the agonistic action of endogenous LXR ligands...
  7. ncbi request reprint Design, synthesis, and biological evaluation of thio-containing compounds with serum HDL-cholesterol-elevating properties
    Hassan Elokdah
    Medicinal Chemistry, Wyeth Research, CN 8000, Princeton, New Jersey 08543, USA
    J Med Chem 47:681-95. 2004
    ..Further evaluation of selected compounds in a dose-response paradigm culminated in the identification of compound 2.39 as a candidate compound for advanced preclinical studies...
  8. ncbi request reprint Modulation of adipose tissue development by pharmacological inhibition of PAI-1
    David L Crandall
    Cardiovascular and Metabolic Disease Research, Wyeth Research, N2265A, PO Box 42528, Philadelphia, PA 19101, USA
    Arterioscler Thromb Vasc Biol 26:2209-15. 2006
    ..The effect of a novel small molecule plasminogen activator inhibitor (PAI-1) inhibitor on adipose tissue physiology was investigated...